Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFFR-Targeting CAR T Cells for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT07758673Phase 1Not yet recruiting
- Sponsor
- City of Hope
- Start
- Apr 2027
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in B cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoblastic lymphoma (B-LBL), sponsored by City of Hope. Primary endpoints: Incidence of adverse events up to 28 days and Dose-limiting toxicity up to 28 days. Planned start Apr 2027; status: not yet recruiting.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell lymphoblastic lymphoma (B-LBL)
Beyond the preview
Go deeper on NCT07758673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07758673.